Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUE Cue Biopharma	$0.83 +1.8%	$0.77	$0.45 ▼ $1.99	$63.48M	1.53	256,508 shs	172,800 shs
LRMR Larimar Therapeutics	$3.91 +6.0%	$3.36	$1.61 ▼ $9.50	$323.67M	0.93	1.08 million shs	1.42 million shs
PRQR ProQR Therapeutics	$2.26 +2.3%	$2.13	$1.07 ▼ $4.62	$237.78M	0.43	421,257 shs	460,691 shs
TRDA Entrada Therapeutics	$6.14 +4.6%	$6.41	$4.93 ▼ $21.79	$233.57M	-0.12	152,930 shs	198,835 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUE Cue Biopharma	+0.37%	+2.71%	-9.74%	+22.68%	-10.35%
LRMR Larimar Therapeutics	-2.12%	-13.38%	+9.17%	+97.33%	-54.67%
PRQR ProQR Therapeutics	+3.27%	+9.41%	-3.07%	+32.34%	+5.24%
TRDA Entrada Therapeutics	+10.55%	+11.81%	-7.99%	-21.73%	-64.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CUE Cue Biopharma	2.6927 of 5 stars	0.0	5.0	4.7	2.9	0.8	0.6
LRMR Larimar Therapeutics	2.2639 of 5 stars	3.6	1.0	0.0	2.0	3.3	0.0
PRQR ProQR Therapeutics	2.6881 of 5 stars	3.6	5.0	0.0	2.6	0.0	0.0
TRDA Entrada Therapeutics	2.9928 of 5 stars	3.5	3.0	0.0	2.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CUE Cue Biopharma	0.00	N/A	N/A	N/A
LRMR Larimar Therapeutics	3.10	Buy	$18.43	371.32% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	253.98% Upside
TRDA Entrada Therapeutics	3.00	Buy	$25.67	318.02% Upside

Current Analyst Ratings Breakdown

Latest CUE, LRMR, TRDA, and PRQR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	LRMR Larimar Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$22.00 ➝ $18.00
8/8/2025	PRQR ProQR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
8/8/2025	TRDA Entrada Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/11/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
6/24/2025	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/24/2025	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $15.00
6/24/2025	LRMR Larimar Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$26.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CUE Cue Biopharma	$8.29M	7.70	N/A	N/A	$0.24 per share	3.46
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$1.45 per share	N/A
PRQR ProQR Therapeutics	$20.46M	11.62	N/A	N/A	$0.72 per share	3.14
TRDA Entrada Therapeutics	$210.78M	1.11	$1.83 per share	3.35	$9.98 per share	0.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CUE Cue Biopharma	-$40.67M	-$0.56	N/A	N/A	N/A	-469.35%	-230.13%	-111.16%	N/A
LRMR Larimar Therapeutics	-$80.60M	-$1.56	N/A	N/A	N/A	N/A	-62.92%	-53.98%	10/29/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.04M	-$0.46	N/A	N/A	N/A	-238.52%	-61.25%	-28.13%	11/6/2025 (Estimated)
TRDA Entrada Therapeutics	$65.63M	-$1.78	N/A	N/A	N/A	-92.30%	-17.81%	-14.55%	11/4/2025 (Estimated)

Latest CUE, LRMR, TRDA, and PRQR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	LRMR Larimar Therapeutics	-$0.47	-$0.41	+$0.06	-$0.41	N/A	N/A
8/12/2025	Q2 2025	CUE Cue Biopharma	-$0.13	-$0.09	+$0.04	-$0.09	$2.00 million	$2.95 million
8/7/2025	Q2 2025	PRQR ProQR Therapeutics	-$0.08	-$0.14	-$0.06	-$0.14	$5.01 million	$4.33 million
8/6/2025	Q2 2025	TRDA Entrada Therapeutics	-$0.86	-$1.04	-$0.18	-$1.04	$8.17 million	$1.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CUE Cue Biopharma	0.01	1.60	1.60
LRMR Larimar Therapeutics	N/A	5.46	7.48
PRQR ProQR Therapeutics	N/A	3.76	3.76
TRDA Entrada Therapeutics	N/A	18.64	18.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CUE Cue Biopharma	35.04%
LRMR Larimar Therapeutics	91.92%
PRQR ProQR Therapeutics	32.65%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
CUE Cue Biopharma	10.78%
LRMR Larimar Therapeutics	4.50%
PRQR ProQR Therapeutics	8.40%
TRDA Entrada Therapeutics	8.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CUE Cue Biopharma	60	76.85 million	68.56 million	Optionable
LRMR Larimar Therapeutics	30	82.78 million	79.05 million	Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable
TRDA Entrada Therapeutics	110	38.04 million	34.95 million	Optionable

CUE, LRMR, TRDA, and PRQR Headlines

Recent News About These Companies

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives $25.67 Average Target Price from Analysts

August 18, 2025 | americanbankingnews.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Average Rating of "Buy" from Brokerages

August 17, 2025 | marketbeat.com

Roth Capital Has Pessimistic Outlook of TRDA Q3 Earnings

August 12, 2025 | americanbankingnews.com

What is William Blair's Forecast for TRDA Q3 Earnings?

August 12, 2025 | americanbankingnews.com

Entrada (TRDA) Q2 Revenue Drops 98%

August 11, 2025 | theglobeandmail.com

Entrada Therapeutics (NASDAQ:TRDA) Rating Lowered to Sell at Wall Street Zen

August 11, 2025 | americanbankingnews.com

HC Wainwright Issues Pessimistic Outlook for TRDA Earnings

August 11, 2025 | marketbeat.com

Roth Capital Issues Pessimistic Forecast for TRDA Earnings

August 11, 2025 | marketbeat.com

William Blair Issues Negative Forecast for TRDA Earnings

August 11, 2025 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Downgraded to Sell Rating by Wall Street Zen

August 10, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

August 9, 2025 | finance.yahoo.com

Entrada Therapeutics (TRDA) to Release Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

August 6, 2025 | globenewswire.com

Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?

July 31, 2025 | zacks.com

5am Ventures v sells Entrada Therapeutics (TRDA) stock for $202k

July 13, 2025 | investing.com

Entrada therapeutics (TRDA) director Parmar sells $202k in stock

July 13, 2025 | investing.com

Ventures V. L.P. 5Am Sells 6,935 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

July 12, 2025 | insidertrades.com

Entrada Therapeutics (TRDA) 10% owners sell $866k in stock

July 3, 2025 | investing.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 6,422 Shares

July 2, 2025 | insidertrades.com

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 3, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE, LRMR, TRDA, and PRQR Company Descriptions

Cue Biopharma NASDAQ:CUE

$0.83 +0.01 (+1.80%)

Closing price 04:00 PM Eastern

Extended Trading

$0.83 +0.00 (+0.48%)

As of 04:33 PM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Larimar Therapeutics NASDAQ:LRMR

$3.91 +0.22 (+5.96%)

Closing price 04:00 PM Eastern

Extended Trading

$3.86 -0.04 (-1.15%)

As of 06:41 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

ProQR Therapeutics NASDAQ:PRQR

$2.26 +0.05 (+2.26%)

Closing price 04:00 PM Eastern

Extended Trading

$2.34 +0.08 (+3.54%)

As of 06:39 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Entrada Therapeutics NASDAQ:TRDA

$6.14 +0.27 (+4.60%)

Closing price 04:00 PM Eastern

Extended Trading

$6.14 +0.00 (+0.08%)

As of 04:10 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time